BBG2Na an RSV subunit vaccine candidate intramuscularly injected to human confers protection against viral challenge after nasal immunization in mice

Détails

ID Serval
serval:BIB_699563EE8FA2
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
BBG2Na an RSV subunit vaccine candidate intramuscularly injected to human confers protection against viral challenge after nasal immunization in mice
Périodique
Vaccine
Auteur(s)
Goetsch  L., Plotnicky-Gilquin  H., Aubry  J. P., De-Lys  P., Haeuw  J. F., Bonnefoy  J. Y., Nguyen  N. T., Corvaia  N., Velin  D.
ISSN
0264-410X (Print)
Statut éditorial
Publié
Date de publication
07/2001
Volume
19
Numéro
28-29
Pages
4036-42
Notes
Journal Article --- Old month value: Jul 16
Résumé
Respiratory syncytial virus (RSV) is a major respiratory pathogen responsible for severe pulmonary disease. We have developed a parenterally administered vaccine, BBG2Na, which is currently in a phase III clinical trial. BBG2Na comprises residues 130--230 of RSV-A G protein (G2Na) fused to the BB carrier protein. In this study, we show that BBG2Na can be delivered by the nasal route and generates both mucosal and systemic antibody responses when co-administered with cholera toxin B or a newly described delivery system, zwittergent 3--14. We found that nasal BBG2Na administration protects against RSV challenge and does not induce lung immunopathology upon subsequent RSV challenge.
Mots-clé
Administration, Intranasal Animals Antibodies, Viral/biosynthesis Cholera Toxin/administration & dosage Female HN Protein/immunology Humans Immunity, Mucosal Injections, Intramuscular Mice Mice, Inbred BALB C Nasal Mucosa/drug effects/pathology Quaternary Ammonium Compounds/administration & dosage/toxicity Respiratory Syncytial Virus Vaccines/*administration & dosage Respiratory Syncytial Viruses/*immunology Vaccines, Subunit/administration & dosage Viral Envelope Proteins
Pubmed
Web of science
Création de la notice
25/01/2008 17:10
Dernière modification de la notice
20/08/2019 15:24
Données d'usage